| Dermatology and Skin Diseases | Lifetime | 442 | IT 23 | 97.82 |
| Drug-Induced Adverse Reactions | Lifetime | 248 | IT 13 | 96.41 |
| IL-33, ST2, and ILC Pathways | Lifetime | 337 | IT 16 | 96.76 |
| Urticaria and Related Conditions | Lifetime | 435 | IT 27 | 96.47 |
| Allergic Rhinitis and Sensitization | Lifetime | 952 | IT 55 | 96.60 |
| Inflammasome and immune disorders | Lifetime | 742 | IT 52 | 94.12 |
| Psoriasis: Treatment and Pathogenesis | Lifetime | 670 | IT 73 | 95.21 |
| Food Allergy and Anaphylaxis Research | Lifetime | 851 | IT 51 | 94.81 |
| Contact Dermatitis and Allergies | Lifetime | 731 | IT 45 | 94.75 |
| Whipple's Disease and Interleukins | Lifetime | 253 | IT 11 | 80.11 |
| Herbal Medicine Research Studies | Lifetime | 647 | IT 39 | 78.73 |
| Bioactive Compounds in Plants | Lifetime | 291 | IT 13 | 66.84 |
| Medicinal Plant Extracts Effects | Lifetime | 481 | IT 14 | 67.45 |
| IL-33, ST2, and ILC Pathways | 2021-2025 | 16 | IT 1 | 98.26 |
| Immune Cell Function and Interaction | 2021-2025 | 460 | IT 15 | 94.53 |
| Dermatology and Skin Diseases | 2021-2025 | 218 | IT 29 | 96.82 |
| Asthma and respiratory diseases | 2021-2025 | 329 | IT 49 | 97.00 |
| Vitamin D Research Studies | 2021-2025 | 148 | IT 16 | 91.82 |
| Allergic Rhinitis and Sensitization | 2021-2025 | 328 | IT 37 | 94.66 |
| Skin Protection and Aging | 2021-2025 | 181 | IT 16 | 90.95 |
| Herbal Medicine Research Studies | 2021-2025 | 26 | IT 3 | 83.40 |
| Systemic Sclerosis and Related Diseases | 2021-2025 | 394 | IT 83 | 90.00 |
| Urticaria and Related Conditions | 2021-2025 | 332 | IT 26 | 88.87 |
| Eosinophilic Esophagitis | 2021-2025 | 586 | IT 83 | 88.50 |
| Psoriasis: Treatment and Pathogenesis | 2021-2025 | 528 | IT 84 | 88.72 |
| Food Allergy and Anaphylaxis Research | 2021-2025 | 476 | IT 42 | 88.64 |
| Mast cells and histamine | 2021-2025 | 233 | IT 16 | 84.74 |
| melanin and skin pigmentation | 2021-2025 | 367 | IT 29 | 81.24 |
| Advanced Glycation End Products research | 2021-2025 | 463 | IT 17 | 72.02 |
| Drug-Induced Adverse Reactions | 2021-2025 | 814 | IT 66 | 68.97 |
| S100 Proteins and Annexins | 2021-2025 | 751 | IT 45 | 64.12 |